Efficacy of rituximab in the treatment of epidermolysis bullosa acquisita.

Autor:	Bratsos SP; St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Demir Z; St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Mee JB; St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Groves RW; St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Tull TJ; St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Jazyk:	angličtina
Zdroj:	Clinical and experimental dermatology [Clin Exp Dermatol] 2024 Jul 25. Date of Electronic Publication: 2024 Jul 25.
DOI:	10.1093/ced/llae283
Abstrakt:	Background: Epidermolysis bullosa acquisita (EBA) is a chronic mucocutaneous disease that is mediated by antibodies that bind collagen VII. The treatment of EBA can be challenging and often multiple immunomodulatory drugs are required. Rituximab has been reported to be an effective treatment for recalcitrant EBA, although its evidence base is limited to case reports and case series. This study therefore aimed to evaluate the efficacy of rituximab in patients with EBA. Methods: EBA patients treated with rituximab were identified by searching electronic medical records. Diagnostic criteria for EBA were as follows; mechanobullous skin lesions and / or mucosal ulceration, indirect immunofluorescence localising to the base of salt split skin and positive collagen VII antibodies. Clinical disease activity, collagen VII antibody levels and serum immunoglobulins were recorded at each follow up visit over 600 day period. Treatment responses were classified as follows; complete remission (CR) as the absence of new or established lesions on minimal therapy for 2 months, partial remission (PR) as transient lesions that heal within 1 week on minimal therapy and active disease (AD) as the development of new lesions. Results: 14 patients with EBA were treated with rituximab. CR or PR was observed in 11 patients, and the duration of response varied between 4 and 24 months. A reduction in collagen VII antibody levels was observed in all patients. No significant adverse events were reported. Conclusions: Rituximab is a safe and effective treatment for patients with recalcitrant EBA although there was significant heterogeneity in the disease response. (© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu